Literature DB >> 16201406

The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin.

Ellen A J Thomassen1, Harrie A van Veen, Patrick H C van Berkel, Jan H Nuijens, Jan Pieter Abrahams.   

Abstract

Human lactoferrin (hLF) is an iron-binding glycoprotein involved in the host defence against infection and excessive inflammation. As the availability of (human milk-derived) natural hLF is limited, alternative means of production of this biopharmaceutical are extensively researched. Here we report the crystal structure of recombinant hLF (rhLF) expressed in the milk of transgenic cows at a resolution of 2.4 A. To our knowledge, the first reported structure of a recombinant protein produced in milk of transgenic livestock. Even though rhLF contains oligomannose- and hybrid-type N-linked glycans next to complex-type glycans, which are the only glycans found on natural hLF, the structures are identical within the experimental error (r.m.s. deviation of only 0.28 A for the main-chain atoms). Of the differences in polymorphic amino acids between the natural and rhLF variant used, only the side-chain of Asp561 could be modeled into the rhLF electron density map. Taken together, the results confirm the structural integrity of the rhLF variant used in this study. It also confirms the validity of the transgenic cow mammary gland as a vehicle to produce recombinant human proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16201406     DOI: 10.1007/s11248-005-3233-0

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  32 in total

Review 1.  Structure and biological actions of lactoferrin.

Authors:  J H Nuijens; P H van Berkel; F L Schanbacher
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-07       Impact factor: 2.673

2.  WHAT IF: a molecular modeling and drug design program.

Authors:  G Vriend
Journal:  J Mol Graph       Date:  1990-03

Review 3.  Biological role of lactoferrin.

Authors:  L Sánchez; M Calvo; J H Brock
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

4.  Automated refinement for protein crystallography.

Authors:  V S Lamzin; K S Wilson
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

5.  Metal ligand-induced alterations in the surface structures of lactoferrin and transferrin probed by interaction with immobilized copper(II) ions.

Authors:  T W Hutchens; T T Yip
Journal:  J Chromatogr       Date:  1991-01-04

6.  Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin.

Authors:  R T Ellison; T J Giehl; F M LaForce
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

7.  Modulation of classical C3 convertase of complement by tear lactoferrin.

Authors:  A Kijlstra; S H Jeurissen
Journal:  Immunology       Date:  1982-10       Impact factor: 7.397

8.  Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin-1.

Authors:  J R Zucali; H E Broxmeyer; D Levy; C Morse
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

9.  The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis.

Authors:  Harrie A van Veen; Marlieke E J Geerts; Patrick H C van Berkel; Jan H Nuijens
Journal:  Eur J Biochem       Date:  2004-02

10.  Structure of human diferric lactoferrin refined at 2.2 A resolution.

Authors:  M Haridas; B F Anderson; E N Baker
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1995-09-01
View more
  8 in total

1.  A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice.

Authors:  Shen-An Hwang; Katarzyna Wilk; Marian L Kruzel; Jeffrey K Actor
Journal:  Vaccine       Date:  2009-04-05       Impact factor: 3.641

Review 2.  Production of human lactoferrin and lysozyme in the milk of transgenic dairy animals: past, present, and future.

Authors:  Caitlin A Cooper; Elizabeth A Maga; James D Murray
Journal:  Transgenic Res       Date:  2015-06-10       Impact factor: 2.788

3.  Transgenic cows that produce recombinant human lactoferrin in milk are not protected from experimental Escherichia coli intramammary infection.

Authors:  P Hyvönen; L Suojala; T Orro; J Haaranen; O Simola; C Røntved; S Pyörälä
Journal:  Infect Immun       Date:  2006-09-05       Impact factor: 3.441

4.  Structure of a complex of human lactoferrin N-lobe with pneumococcal surface protein a provides insight into microbial defense mechanism.

Authors:  Olga Senkovich; William J Cook; Shaper Mirza; Susan K Hollingshead; Irina I Protasevich; David E Briles; Debasish Chattopadhyay
Journal:  J Mol Biol       Date:  2007-05-10       Impact factor: 5.469

5.  Characterization of recombinant human lactoferrin N-glycans expressed in the milk of transgenic cows.

Authors:  Annabelle Le Parc; Sercan Karav; Camille Rouquié; Elizabeth A Maga; Apichaya Bunyatratchata; Daniela Barile
Journal:  PLoS One       Date:  2017-02-07       Impact factor: 3.240

Review 6.  Studying Lactoferrin N-Glycosylation.

Authors:  Sercan Karav; J Bruce German; Camille Rouquié; Annabelle Le Parc; Daniela Barile
Journal:  Int J Mol Sci       Date:  2017-04-20       Impact factor: 5.923

7.  Regulation of Iron Homeostasis through Parkin-Mediated Lactoferrin Ubiquitylation.

Authors:  Ankur A Gholkar; Stefan Schmollinger; Erick F Velasquez; Yu-Chen Lo; Whitaker Cohn; Joseph Capri; Harish Dharmarajan; William J Deardorff; Lucy W Gao; Mai Abdusamad; Julian P Whitelegge; Jorge Z Torres
Journal:  Biochemistry       Date:  2020-08-06       Impact factor: 3.321

Review 8.  Lactoferrin's Anti-Cancer Properties: Safety, Selectivity, and Wide Range of Action.

Authors:  Antimo Cutone; Luigi Rosa; Giusi Ianiro; Maria Stefania Lepanto; Maria Carmela Bonaccorsi di Patti; Piera Valenti; Giovanni Musci
Journal:  Biomolecules       Date:  2020-03-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.